Trial Profile
The Effect of NEPRIlysin (LCZ696) on EXercise TOLerance, Muscle Vasodilatation, Muscle Strength and Body Composition in Patients With Heart Failure - NEPRIExTol-HF Trial
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Sacubitril/valsartan (Primary) ; Enalapril
- Indications Heart failure
- Focus Therapeutic Use
- Acronyms NEPRIExTol-HF
- 13 May 2021 Primary endpoint (Exercise tolerance) has not been met as per results published in the American Heart Journal
- 13 May 2021 Results published in the American Heart Journal
- 21 Oct 2020 Status changed from active, no longer recruiting to completed.